PureTech Health's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.92.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.71.
During the past 3 years, the average EBIT per Share Growth Rate was 18.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PureTech Health's EBIT per Share or its related term are showing as below:
PRTCY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -218.3 Med: -11.2 Max: 18.7
Current: 18.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of PureTech Health was 18.70% per year. The lowest was -218.30% per year. And the median was -11.20% per year.
PRTCY's 3-Year EBIT Growth Rate is ranked better than 54.68% of 1185
companies
in the Biotechnology industry
Industry Median: 15.4
vs PRTCY: 18.70
PureTech Health's EBIT for the
six
months ended in Dec. 2025 was $-22.24 Mil.
PureTech Health (OTCPK:PRTCY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PureTech Health EBIT per Share Related Terms
PureTech Health EBIT per Share Historical Data
* Premium members only.
The historical data trend for PureTech Health's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a EBIT per Share of $-2.71 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #537 out of 1185 companies in the Biotechnology industry, placing it in the top 45.3%.
Is PureTech Health's EBIT per Share too high?
PureTech Health's current EBIT per Share is $-2.71. Based on the distribution chart, PureTech Health ranks #537 out of 1185 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #537 out of 1185 companies for EBIT per Share. This puts PureTech Health in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,185 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current EBIT per Share is $-2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current EBIT per Share is $-2.71. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PureTech Health (PRTCY), the current EBIT per Share is $-2.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
EBIT per Share: $-2.71
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
